A teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia was hospitalized and recovered in 15 days. The immunophenotyping analysis of peripheral blood cells was performed in two time points: the first was 1 month before (pre-infection) while the second was during COVID-19 pneumonia (infection). At the infection time point, no differences in the percentages of immune activation and immunesenescence of CD4+ and CD8+ T-cells were observed compared to the pre-infection time point. Our evaluation seems to confirm that teriflunomide controls T-cells immune activation and immunosenescence suggesting that teriflunomide should not be discontinued in MS patients with an active COVID-19 pneumonia.
The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia / Ciardi, M. R.; Zingaropoli, M. A.; Pasculli, P.; Perri, V.; Tartaglia, M.; Valeri, S.; Russo, G.; Conte, A.; Mastroianni, C. M.. - In: JOURNAL OF NEUROIMMUNOLOGY. - ISSN 0165-5728. - 346:(2020), pp. 1-4. [10.1016/j.jneuroim.2020.577323]
Titolo: | The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia | |
Autori: | MASTROIANNI, Claudio Maria (Ultimo) | |
Data di pubblicazione: | 2020 | |
Rivista: | ||
Citazione: | The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia / Ciardi, M. R.; Zingaropoli, M. A.; Pasculli, P.; Perri, V.; Tartaglia, M.; Valeri, S.; Russo, G.; Conte, A.; Mastroianni, C. M.. - In: JOURNAL OF NEUROIMMUNOLOGY. - ISSN 0165-5728. - 346:(2020), pp. 1-4. [10.1016/j.jneuroim.2020.577323] | |
Handle: | http://hdl.handle.net/11573/1434151 | |
Appartiene alla tipologia: | 01a Articolo in rivista |
File allegati a questo prodotto
File | Note | Tipologia | Licenza | |
---|---|---|---|---|
Ciardi_peripheral_2020.pdf | Versione editoriale (versione pubblicata con il layout dell'editore) | Tutti i diritti riservati (All rights reserved) | Administrator Richiedi una copia |